AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
195.15
+11.29 (6.14%)
At close: Jul 2, 2026, 4:00 PM EDT
193.00
-2.15 (-1.10%)
After-hours: Jul 2, 2026, 7:55 PM EDT
AstraZeneca Employees
AstraZeneca had 95,100 employees as of December 31, 2025. The number of employees increased by 2,200 or 2.37% compared to the previous year.
Employees
95,100
Change (1Y)
2,200
Growth (1Y)
2.37%
Revenue / Employee
$635,531
Profits / Employee
$109,243
Market Cap
299.41B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 95,100 | 2,200 | 2.37% |
| Dec 31, 2024 | 92,900 | 3,000 | 3.34% |
| Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
| Dec 31, 2022 | 83,500 | 400 | 0.48% |
| Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
| Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
| Dec 31, 2019 | 70,600 | 6,000 | 9.29% |
| Dec 31, 2018 | 64,600 | 3,500 | 5.73% |
| Dec 31, 2017 | 61,100 | 1,400 | 2.35% |
| Dec 31, 2016 | 59,700 | -1,800 | -2.93% |
| Dec 31, 2015 | 61,500 | 4,000 | 6.96% |
| Dec 31, 2014 | 57,500 | 6,000 | 11.65% |
| Dec 31, 2013 | 51,500 | -200 | -0.39% |
| Dec 31, 2012 | 51,700 | -5,500 | -9.62% |
| Dec 31, 2011 | 57,200 | -3,800 | -6.23% |
| Dec 31, 2010 | 61,000 | -1,700 | -2.71% |
| Dec 31, 2009 | 62,700 | -2,300 | -3.54% |
| Dec 31, 2008 | 65,000 | -2,400 | -3.56% |
| Dec 31, 2007 | 67,400 | 600 | 0.90% |
| Dec 31, 2006 | 66,800 | 1,500 | 2.30% |
| Dec 31, 2005 | 65,300 | 1,100 | 1.71% |
| Dec 31, 2004 | 64,200 | 1,600 | 2.56% |
| Dec 31, 2003 | 62,600 | 3,400 | 5.74% |
| Dec 31, 2002 | 59,200 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
AZN News
- 2 days ago - AstraZeneca PLC (AZN) Stock Up 6.1% but GF Value Says Overvalued -- GF Score: 76/100 - GuruFocus
- 3 days ago - AstraZeneca signs CSPC China deal for experimental kidney disease drugs - Reuters
- 3 days ago - Abbisko Therapeutics Partners with AstraZeneca on Lung Cancer Therapy - GuruFocus
- 3 days ago - Abbisko Therapeutics And AstraZeneca Enter Strategic Collaboration For Lumipodlin - Nasdaq
- 3 days ago - AstraZeneca, Abbisko Therapeutics enter strategic collaboration - TheFly
- 3 days ago - Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC - PRNewsWire
- 3 days ago - AstraZeneca PLC (AZN) Shares Fall 3.0% -- What GF Score of 76 Tells Investors - GuruFocus
- 4 days ago - AstraZeneca (AZN) Faces Competition from Anthropic's New AI in Pharma Research - GuruFocus